N-palmitoyl-glycine amide | 133848-35-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-palmitoyl-glycine amide
• 英文别名: Palmitoylamino-essigsaeure-amid；Palmitoylamino-acetamid；N-Palmitoyl-glycin-amid；Hexadecanamide, N-(2-amino-2-oxoethyl)-；N-(2-amino-2-oxoethyl)hexadecanamide
• CAS: 133848-35-8
• 化学式: C₁₈H₃₆N₂O₂
• 分子量: 312.496
• InChiKey: ONYIYPVBLNPMLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  22
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  72.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  棕榈酰甘氨酸 在 盐酸 、 甲醇 、 氨 作用下， 生成 N-palmitoyl-glycine amide
  参考文献：
  名称：

  Koebner, Journal of the Chemical Society, 1941, p. 565

  摘要：

  DOI：

文献信息

• [EN] PRODUCTS AND METHODS FOR THE TREATMENT OF MIXTURES OF WATER AND HYDROPHOBIC LIQUIDS<br/>[FR] PRODUITS ET PROCÉDÉS POUR LE TRAITEMENT DE MÉLANGES D'EAU ET DE LIQUIDES HYDROPHOBES
  申请人：B C RES INC

  公开号：WO2019232629A1

  公开（公告）日：2019-12-12

  Chemical-based methods and products for mitigating the impact of an oil spill are disclosed. The products act by herding, thickening, gelling, and reducing adhesiveness. N-fatty acid amino acid (FA-AA) conjugates display oil-herding behavior when formulated as a free acid in water-miscible organic solvents. A water-miscible organic solvent is not required if the FA-AA conjugate is formulated as a salt. Various salts of FA-AA conjugates are water soluble and can herd oils and increase the thickness of the oil layer. Replacement of the acid group of fatty acid α-amino acid conjugates with other groups that act as hydrogen bond donors and acceptors results in potent phase selective organo-gellants. The oil spill herders can be prepared from bio-based feedstocks and are biodegradable. The oil thickeners or gellants, which are prepared from bio-based feedstocks, have low toxicity, high capacity for oil and reduce the need to use an organic solvent to apply the thickener or gellant to the oil and water mixture in order to gel the oil phase. Formulae (IB), (II), (III)

  本发明涉及化学方法和产品，用于减轻油污泄漏的影响。这些产品通过聚集、增稠、胶化和降低粘性来发挥作用。当N-脂肪酸氨基酸（FA-AA）共轭物被制成水溶性有机溶剂中的自由酸时，它们具有聚集油的行为。如果FA-AA共轭物被制成盐，则不需要水溶性有机溶剂。各种FA-AA共轭物的盐是水溶性的，可以聚集油并增加油层的厚度。将脂肪酸α-氨基酸共轭物的酸基替换为其他作为氢键供体和受体的基团，可以得到有效的相选择性有机胶凝剂。这些油污聚集剂可以从生物基原料制备，并且是可生物降解的。从生物基原料制备的油稠剂或胶凝剂具有低毒性，对油具有高容量，并且减少了使用有机溶剂将稠剂或胶凝剂应用于油水混合物以胶化油相的需要。公式（IB）、（II）、（III）。
• AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES
  申请人：NOVO NORDISK A/S

  公开号：EP0473700A1

  公开（公告）日：1992-03-11
• PRODUCTS AND METHODS FOR THE TREATMENT OF MIXTURES OF WATER AND HYDROPHOBIC LIQUIDS
  申请人：B.C. RESEARCH INC.

  公开号：US20210230466A1

  公开（公告）日：2021-07-29

  Chemical-based methods and products for mitigating the impact of an oil spill are disclosed. The products act by herding, thickening, gelling, and reducing adhesiveness. N-fatty acid amino acid (FA-AA) conjugates display oil-herding behavior when formulated as a free acid in water-miscible organic solvents. A water-miscible organic solvent is not required if the FA-AA conjugate is formulated as a salt. Various salts of FA-AA conjugates are water soluble and can herd oils and increase the thickness of the oil layer. Replacement of the acid group of fatty acid α-amino acid conjugates with other groups that act as hydrogen bond donors and acceptors results in potent phase selective organo-gellants. The oil spill herders can be prepared from bio-based feedstocks and are biodegradable. The oil thickeners or gellants, which are prepared from bio-based feedstocks, have low toxicity, high capacity for oil and reduce the need to use an organic solvent to apply the thickener or gellant to the oil and water mixture in order to gel the oil phase. Formulae (IB), (II), (III)
• [EN] AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES
  申请人：NOVO NORDISK A/S

  公开号：WO1990014429A1

  公开（公告）日：1990-11-29

  (EN) Compounds of general formula (I) or (II), wherein R is an optionally substituted alkyl group with 3-23 carbon atoms, and R1 is hydrogen or an optionally substituted branched or straight-chain, saturated or unsaturated, aliphatic or aromatic hydrocarbon group, are prepared by reacting a compound of the general formula (III): RCOOR2, wherein R2 is H or an alkyl group with 1-6 carbon atoms, and R is as defined above, with a compound of general formula (IV), wherein R1 is as defined above, in the presence of an enzyme capable of catalysing the formation of amide bonds, in particular a lipase. The amide group may be removed from the compound (I) by means of a second enzyme capable of selectively cleaving amide bonds, e.g. a carboxypeptidase, resulting in the compound (II).(FR) Des composés de formule générale (I) ou (II), où R est un groupe alcoyle substitué ou non ayant 3-23 atomes de carbone et R1 est l'hydrogène ou un groupe substitué ou non, à chaîne linéaire ou ramifiée d'hydrocarbures aliphatiques ou aromatiques, saturés ou non saturés, sont préparés en faisant réagir un composé de formule générale (II) où R2 est H ou un groupe alcoyle ayant 1-6 atomes de carbone et R correspond à la définition ce-dessus, avec un composé de formule générale (IV) où R est comme défini ci-dessus, en présence d'une enzyme pouvant catalyser la formation de liaisons d'amides, en particulier, une lipase. On peut extraire le groupe amide présent dans le composé (I) à l'aide d'une deuxième enzyme pouvant cliver les liaisons d'amides, par exemple, une carboxypeptidase, ainsi réalisant le composé (II).
• [EN] PTHR1 RECEPTOR COMPOUNDS<br/>[FR] COMPOSÉS DE RÉCEPTEURS PTHR1
  申请人：ANCHOR THERAPEUTICS INC

  公开号：WO2010053548A2

  公开（公告）日：2010-05-14

  The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor PTHRl, also known as parathyroid hormone/parathyroid hormone related protein receptor. The PTHRl compounds are derived from the intracellular loops and domains of the PTHRl receptor. The invention also relates to the use of these PTHRl receptor compounds and pharmaceutical compositions comprising the PTHRl receptor compounds in the treatment of diseases and conditions associated with PTHRl receptor modulation, such as osteoporosis; humoral hypercalcemia of malignancy; osteolytic and osteoblastic metastasis to bone; primary and secondary hyperparathyroidism associated increase in bone absorption; vascular calcification; psychiatric disorders and cognitive disorders associated with hyperparathyroidism; dermatological disorders; and excess hair growth.